Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$106.39 USD
+0.50 (0.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $106.36 -0.03 (-0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.39 USD
+0.50 (0.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $106.36 -0.03 (-0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs
by Zacks Equity Research
Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
by Zacks Equity Research
Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.
AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business
by Zacks Equity Research
AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.
Bristol Myers (BMY) Gets FDA Nod for Data Addition to Camzyos
by Zacks Equity Research
Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos.
Roche (RHHBY) Gets FDA Approval for Blood Cancer Drug Columvi
by Zacks Equity Research
Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Acadia Healthcare (ACHC) Expands With New Hospital in Michigan
by Zacks Equity Research
Acadia Healthcare's (ACHC) partnership with Bronson Healthcare to expand its footprint in Michigan with Bronson Behavioral Health Hospital.
Wall Street Analysts See a 44.32% Upside in Ligand (LGND): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 44.3% upside potential for Ligand (LGND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2seventy (TSVT) Down 9% on Patient Death in Leukemia Study
by Zacks Equity Research
Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.
Journey Medical (DERM) Up on Rosacea Candidate's Positive Data
by Zacks Equity Research
Journey Medical's (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.
Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why
by Zacks Equity Research
Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug in patients with B-cell non-hodgkin's lymphoma and multiple myeloma.
First Wave (FWBI) Surges 33% on Finishing Enrolment in CF Study
by Zacks Equity Research
First Wave (FWBI) completes enrolment in a mid-stage study evaluating its investigational oral capsule in patients with cystic fibrosis. Topline data from the study is expected next month.
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.
Roche (RHHBY) Announces Positive Results From PNH Studies
by Zacks Equity Research
Roche (RHHBY) crovalimab achieves disease control in paroxysmal nocturnal hemoglobinuria patients in the phase III COMMODORE 1 and COMMODORE 2 studies.
Novartis (NVS) Sandoz Presents Standalone Growth Strategy
by Zacks Equity Research
Novartis generic arm, Sandoz, which will be spun off, expects strong growth as a standalone company, driven by increasing contribution from biosimilars.
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ligand Pharmaceuticals (LGND) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Intercept (ICPT) Announces Positive Data From PBC Study
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
by Zacks Equity Research
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
LGND or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health
by Zacks Equity Research
UnitedHealth (UNH) offers to combine its Optum business with Amedisys to expand its reach in the healthcare-at-home market.
Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.
Novartis Announces Positive Data on Breast Cancer Drug Kisqali
by Zacks Equity Research
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
by Zacks Equity Research
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
by Zacks Equity Research
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
by Zacks Equity Research
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.